Skip to content

High Dose Cholecalciferol to Reduce the Incidence of Gestational Diabetes in High Risk Pregnant Women

A Randomized Single-Center Study of the Effects of High-Dose Cholecalciferol to Reduce the Incidence of Gestational Diabetes in High-Risk Pregnant Women

Status
Withdrawn
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03037593
Enrollment
0
Registered
2017-01-31
Start date
2017-06-01
Completion date
2020-06-30
Last updated
2019-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

Pregnancy, Gestational Diabetes

Brief summary

Demonstrate dose-dependent relationship between vitamin D supplementation and rates of gestational diabetes.

Detailed description

Determine the effect of increased vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin) on the incidence of gestational diabetes compared to a standard prenatal vitamin among pregnant women at high risk for gestational diabetes. Explore the effect of increased vitamin D supplementation (4000 IU daily + prenatal vitamin), compared to a standard prenatal vitamin, on glycemic control, need for oral hypoglycemic agents and/or insulin, and delivery outcomes among the subset of women who develop gestational diabetes.

Interventions

vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This will be a randomized single-center study with a target study group of 300 women. Women will be followed from enrollment through the remainder of their pregnancy

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Women who are currently pregnant and receiving prenatal care at the Women's Health Specialists Clinic (University of Minnesota Physicians) from either MD/DO or CNM providers 2. Subject established prenatal care no later than the completed 12th week of gestation (12 6/7 weeks) 3. Subject possesses as least one of the following characteristics: 1. BMI greater than or equal to 30 kg/m2 2. History of gestational diabetes in a prior pregnancy 3. History of infant with birth weight of 4500g or greater 4. Subject is capable of giving informed consent

Exclusion criteria

1. Age less than 18 years 2. Multiple gestation pregnancies (twins, triplets or greater multiples) 3. Vitamin D deficiency (defined as less than 20 ng/mL) 4. Preexisting diabetes mellitus defined as either: 1. pre-existing diagnosis prior to current pregnancy 2. failure of three-hour glucose tolerance test in first trimester of pregnancy

Design outcomes

Primary

MeasureTime frameDescription
incidence of gestational diabetesBaseline to Delivery of childeffect of increased vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin) on the incidence of gestational diabetes compared to a standard prenatal vitamin among pregnant women at high risk for gestational diabetes.

Secondary

MeasureTime frameDescription
Prescription for insulin or oral hypoglycemic agentsBaseline to Delivery of childPrescription for insulin or oral hypoglycemic agents
Mode of deliveryDelivery of childNatural or C-Section
Birth weightDelivery of ChildWeight in Kg
Apgar scoreBirth of child to 5 minutes\<7 at 5 minutes
Shoulder DystociaBirth of child

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026